Comparison of the immunomodulatory effects of the plant sterol β-sitosterol to simvastatin in peripheral blood cells from multiple sclerosis patients

• Published in: International immunopharmacology Vol. 9; no. 1; pp. 153 - 157
• Main Authors: Desai, Forum, Ramanathan, Murali, Fink, Carol S., Wilding, Gregory E., Weinstock-Guttman, Bianca, Awad, Atif B.
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier B.V 2009; Elsevier
• Subjects: Adolescent; Adult; Aged; Biological and medical sciences; Blood Cells - drug effects; Blood Cells - immunology; Cell Proliferation - drug effects; Cell Survival - drug effects; Cytokines; Cytokines - biosynthesis; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology; Immunologic Factors - pharmacology; Interleukin-10 - metabolism; Interleukin-12 - metabolism; Interleukin-5 - metabolism; Medical sciences; Middle Aged; Multiple sclerosis; Multiple Sclerosis - blood; Multiple Sclerosis - immunology; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis; Neurology; Pharmacology. Drug treatments; Simvastatin; Simvastatin - pharmacology; Sitosterols - pharmacology; Tumor Necrosis Factor-alpha - metabolism; Young Adult; β-Sitosterol; β-Sitosterol; Multiple sclerosis; Cytokines; Simvastatin; Human; Nervous system diseases; Enzyme; Immunomodulation; Cytokine; Enzyme inhibitor; Statin derivative; Hypocholesterolemic agent; Inflammatory disease; Immunomodulator; Blood cell; Plant; HMG-CoA reductase inhibitor; Phytosterol; Central nervous system disease; Hydroxymethylglutaryl-CoA reductase; Oxidoreductases; Comparative study; Antilipemic agent; Sterol
• ISSN: 1567-5769; 1878-1705
• DOI: 10.1016/j.intimp.2008.10.019

Statins as hypocholesterolimic drugs have recently shown to have ant-inflammatory properties and thus are being assessed for the treatment of multiple sclerosis (MS). Dietary phytosterols such as β-sitosterol (SIT) are also hypocholesterolemic compounds and from preliminary studies they appear to have also anti-inflammatory properties. In this communication, we report on studies to investigate the immunomodulatory effects of SIT on proliferation and release of key cytokines from peripheral blood mononuclear cells (PBMC) of MS patients. In PBMC of MS patients, 16 μM SIT had no effect on cell proliferation; however simvastatin (SV) at 10 and 20 μM reduced cell proliferation by as much as 60%. SIT (4 μM) reduced TNF-α release by 24% in PBMC of MS patients whereas 10 μM SV reduced TNF-α release by 94%. SIT reduced IL-12 release in MS patients at 4 and 16 μM by 27% and 30%, respectively. In healthy subjects, 16 μM SIT increased the anti-inflammatory cytokine IL-10 by 47% whereas 10 μM SV decreased IL-10 by 30%. In PBMC of MS patients, SIT had no effect on IL-10 release whereas 10 μM SV reduced IL-10 by 62%. SIT (4 μM) reduced IL-5 release by 47% in MS patients while 10 μM SV reduced IL-5 by 89%. The results show that SIT is effective in modulating the secretion of pro/anti-inflammatory cytokines and suggest a potential beneficial effect of SIT in MS management without the side effects associated with statin therapy.